Champions Oncology, Inc.
NASDAQ:CSBRBiotechnology
-$0.08 today
- Market cap
- $61.80M
- Beta
- 0.40
- P/E (TTM)
- -41.0
- EPS (TTM)
- -$0.16
Volume 0.01M
Average 0.01M
CSBR EBITDA Margin
EBITDA as a percentage of revenue.
Champions Oncology, Inc.NASDAQ: CSBR
EBITDA Margin · Q3 FY2026 · quarter ended Jan 2026
EBITDA Margin narrows to 0.6%
EBITDA Margin was 0.6% in Q3 FY2026, down 28.2 pp from a year earlier. On a trailing-twelve-month basis it was -1.6%, down 16.1 pp year over year. Over 3 fiscal years it widened by 6.5 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 1 analysts of 5.9% for the fiscal year ending Apr 2026, down from 11.0% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJan 2026
- 0.6%-3.4 pp QoQ
- Last fiscal yearApr 2025
- 11.0%+21.9 pp YoY
- LTMJan 2026
- -1.6%-16.1 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -28.2 pp | +9.8 pp | +38.0 pp |
| 1 year | +21.9 pp | -5.1 pp | -26.9 pp |
| 3 years | +6.5 pp | — | — |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 11.0%
- Year-over-year change
- +21.9pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-04-30 | 11.0% | +21.9pp |
| FY2024 | 2024-04-30 | -10.8% | -5.2pp |
| FY2023 | 2023-04-30 | -5.6% | -10.1pp |
| FY2022 | 2022-04-30 | 4.5% | +0.7pp |
| FY2021 | 2021-04-30 | 3.8% | — |
EBITDA Margin vs competitors
How CSBR compares with its peers on the latest reported figures
- CSBR's LTM Jan 2026 EBITDA Margin of -1.6% is the 2nd highest of the 8 companies compared; the peer median is -4623.1%.
- Its year-over-year change of -16.1 pp is the 2nd highest of 7, against a peer median of -3877.4 pp.
- Over three fiscal years its change of +6.5 pp compares with a peer median of +381.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| FY2025 | 3772.2% | — | +5140.2 pp | |
| LTM Jan 2026 | -1.6% | -16.1 pp | +6.5 pp | |
| LTM Mar 2026 | -23.7% | -20.8 pp | +381.6 pp | |
| LTM Mar 2026 | -106.5% | +169.1 pp | +12.9 pp | |
| LTM Mar 2026 | -4623.1% | -3172.4 pp | +10652.3 pp | |
IMAImageneBio Inc | FY2025 | -5583.3% | -4582.4 pp | -5147.8 pp |
| FY2025 | -85279.7% | -85223.0 pp | — | |
| LTM Mar 2026 | -144435.8% | -111246.8 pp | — | |
ARTVArtiva Biotherapeutics, Inc. | FY2025 | — | — | — |
KLRSKalaris Therapeutics Inc | FY2025 | — | — | — |
| Peer median (excluding CSBR) | -4623.1% | -3877.4 pp | +381.6 pp | |
Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Apr 2021 | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 |
|---|---|---|---|---|---|
| Revenue | 41.04M | 49.11M | 53.87M | 50.16M | 56.94M |
| Cost of Revenue | 21.45M | 23.63M | 29.53M | 29.4M | 28.39M |
| Gross Profit | 19.59M | 25.48M | 24.34M | 20.75M | 28.56M |
| Gross Margin | 47.7% | 51.9% | 45.2% | 41.4% | 50.1% |
| Research & Development | 7.2M | 9.37M | 11.55M | 9.54M | 6.83M |
| Selling, General & Admin | 12.03M | 15.5M | 17.24M | 18.13M | 16.88M |
| Operating Expenses | 19.23M | 24.87M | 28.79M | 27.68M | 23.71M |
| Depreciation & Amortization | 1.18M | 1.63M | 2.25M | 1.87M | 1.64M |
| EBITDA | 1.55M | 2.21M | (3.02M) | (5.44M) | 6.27M |
| EBITDA Margin | 3.8% | 4.5% | -5.6% | -10.8% | 11.0% |
| Operating Income | 366K | 607K | (4.45M) | (6.92M) | 4.85M |
| Operating Margin | 0.9% | 1.2% | -8.3% | -13.8% | 8.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 71K | (24K) | (818K) | (387K) | (220K) |
| Income Before Tax | 437K | 583K | (5.27M) | (7.31M) | 4.63M |
| Pre-Tax Margin | 1.1% | 1.2% | -9.8% | -14.6% | 8.1% |
| Income Tax Expense | 75K | 35K | 68K | (32K) | (75K) |
| Net Income | 362K | 548K | (5.34M) | (7.28M) | 4.7M |
| Net Margin | 0.9% | 1.1% | -9.9% | -14.5% | 8.3% |
| EPS (Basic) | 0.03 | 0.04 | (0.39) | (0.54) | 0.34 |
| EPS (Diluted) | 0.02 | 0.04 | (0.39) | (0.54) | 0.33 |
| Weighted Avg Shares | 13.14M | 13.2M | 13.54M | 13.55M | 13.66M |
| Weighted Avg Shares (Diluted) | 14.57M | 14.16M | 13.54M | 13.55M | 14.27M |
Champions Oncology, Inc.
NASDAQ:CSBR
Intrinsic Alpha fair value
Locked
Current Price
$4.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.